62 research outputs found

    The Mycobacterium Tuberculosis FAS-II Dehydratases and Methyltransferases Define the Specificity of the Mycolic Acid Elongation Complexes

    Get PDF
    BACKGROUND: The human pathogen Mycobacterium tuberculosis (Mtb) has the originality of possessing a multifunctional mega-enzyme FAS-I (Fatty Acid Synthase-I), together with a multi-protein FAS-II system, to carry out the biosynthesis of common and of specific long chain fatty acids: the mycolic acids (MA). MA are the main constituents of the external mycomembrane that represents a tight permeability barrier involved in the pathogenicity of Mtb. The MA biosynthesis pathway is essential and contains targets for efficient antibiotics. We have demonstrated previously that proteins of FAS-II interact specifically to form specialized and interconnected complexes. This finding suggested that the organization of FAS-II resemble to the architecture of multifunctional mega-enzyme like the mammalian mFAS-I, which is devoted to the fatty acid biosynthesis. PRINCIPAL FINDINGS: Based on conventional and reliable studies using yeast-two hybrid, yeast-three-hybrid and in vitro Co-immunoprecipitation, we completed here the analysis of the composition and architecture of the interactome between the known components of the Mtb FAS-II complexes. We showed that the recently identified dehydratases HadAB and HadBC are part of the FAS-II elongation complexes and may represent a specific link between the core of FAS-II and the condensing enzymes of the system. By testing four additional methyltransferases involved in the biosynthesis of mycolic acids, we demonstrated that they display specific interactions with each type of complexes suggesting their coordinated action during MA elongation. SIGNIFICANCE: These results provide a global update of the architecture and organization of a FAS-II system. The FAS-II system of Mtb is organized in specialized interconnected complexes and the specificity of each elongation complex is given by preferential interactions between condensing enzymes and dehydratase heterodimers. This study will probably allow defining essential and specific interactions that correspond to promising targets for Mtb FAS-II inhibitors

    Mu2e Technical Design Report

    Full text link
    The Mu2e experiment at Fermilab will search for charged lepton flavor violation via the coherent conversion process mu- N --> e- N with a sensitivity approximately four orders of magnitude better than the current world's best limits for this process. The experiment's sensitivity offers discovery potential over a wide array of new physics models and probes mass scales well beyond the reach of the LHC. We describe herein the preliminary design of the proposed Mu2e experiment. This document was created in partial fulfillment of the requirements necessary to obtain DOE CD-2 approval.Comment: compressed file, 888 pages, 621 figures, 126 tables; full resolution available at http://mu2e.fnal.gov; corrected typo in background summary, Table 3.

    1438P Trabectedin combined with hyperthermia: Characterization of enhanced drug-efficacy in human tumor cells.

    No full text
    Aim: Trabectedin (Yondelis) is approved for the treatment of patients with advanced soft tissue sarcoma (STS) after failure of anthracyclines and ifosfamide. Its cytostatic activity is associated with the induction of DNA double-strand breaks (DSBs). Regional hyperthermia (RHT) improves chemotherapy of patients with high-risk STS (Issels, Lancet Oncol 2010). The rationale for combined treatment is that heat-mediated degradation of BRCA2 impairs DNA homologous recombination repair (HR) which is crucial for the repair of DSBs (Krawczyk, PNAS 2011). Previously, we have demonstrated that simultaneous treatment of trabectedin and RHT resulted in enhanced cytotoxicity accompanied by elevated DNA-damage (Kampmann, CTOS 2013). Methods: For treatment, trabectedin (5-20nM) was applied for 3 hours with or without RHT (41.8°C or 43°C) for 1.5 hours. Cell cycle arrest and apoptosis were analyzed in the following human cell lines: U2Os (osteosarcoma), SW872 (liposarcoma) DLD1 (colorectal cancer) and DLD1−/-BRCA2 by Nicoletti staining and measuring caspase-activity 24h, 48h and 72h after treatment. The extent of cellular senescence was analyzed by a senescence-associated beta-galactosidase assay 72h and 144h after treatment. Results: Trabectedin treatment induced G2 arrest which was increased and prolonged after adding RHT. Furthermore, trabectedin induced apoptosis dose dependently which was also significantly augmented by RHT. However, the relative amount of apoptosis in U2Os was only half as large as in SW872 or DLD1. Interestingly, trabectedin induced a remarkable amount of senescent cells in U2Os but not in SW872 which again was significantly augmented by RHT. In BRCA2-deficient cells, thermosensitization of trabectedin was significantly reduced. Conclusions: Simultaneous treatment of trabectedin and RHT results in enhanced cytotoxicity accompanied by elevated DNA-damage. BRCA2-degradation and impairment of HR dependent DSB-repair are involved in thermosensitization. Here we discovered cell specific differences in induction of apoptosis or senescence which warrants further investigation. Disclosure: A. Tanovic: Scientific writer of PharmaMar. All other authors have declared no conflicts of interest
    corecore